RSS Feeds
Spironolactone and Endocrine Dysfunction
- D. LYNN LORIAUX, M.D., Ph.D.;
- RAYMOND MENARD, Ph.D.;
- ADDISON TAYLOR, M.D., Ph.D.;
- JULIO C. PITA, M.D.; and
- RICHARD SANTEN, M.D.
Abstract
Therapy with spironolactone is often associated with estrogenlike side-effects, including impotence and gynecomastia in men and menstrual irregularity in women. Several possible mechanisms by which spironolactone could cause these side-effects have been identified. Spironolactone has been shown to affect both gonadal and adrenal steroidogenesis, to elevate plasma gonadotrophin levels in children, and to act as an antiandrogen at the target tissue level. This conference presents a discussion of how these effects might interact to produce the endocrine side effects associated with spironolactone therapy.
Article and Author Information
-
*Head, Endocrinology Service Unit, National Institute of Child Health and Human Development, National Institutes of Health; Bethesda, Maryland.
-
†Assistant Professor, Department of Biochemistry, Rhode Island Hospital; Providence, Rhode Island.
-
▸An edited transciption of a Combined Clinical Staff Conference by the National Institute of Child Health and Human Development, 11 September 1975, at the Clinical Center, National Institutes of Health, Bethesda, Maryland.
-
▸Requests for reprints should be addressed to D. Lynn Loriaux, M.D., Ph.D.; Head, Endocrinology Service Unit, National Institute of Child Health and Human Development, National Institutes of Health; Bethesda, MD 20014.
